Renalytix Plc (AIM:RENX)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 15.84M |
| Revenue (ttm) | 2.19M |
| Net Income (ttm) | -14.89M |
| Shares Out | 437.02M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,029,277 |
| Average Volume | 1,286,660 |
| Open | 3.625 |
| Previous Close | 3.500 |
| Day's Range | 3.500 - 3.750 |
| 52-Week Range | 3.500 - 15.500 |
| Beta | 1.96 |
| RSI | 27.55 |
| Earnings Date | Mar 18, 2026 |
About Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl... [Read more]
Financial Performance
In fiscal year 2025, Renalytix's revenue was $3.00 million, an increase of 30.43% compared to the previous year's $2.30 million. Losses were -$20.40 million, -55.16% less than in 2024.
Financial numbers in USD Financial StatementsNews
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical managem...
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” Throughout the hearings process and pendi...
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage Company has Achieved Prerequ...
Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript
Renalytix Plc (NASDAQ:RNLX) Q3 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer James Sterling - C...
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical manageme...
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, Ma...
Renalytix Announces Financing with Expected Size of up to $4 Million
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75...
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optim...
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTec...
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months
Renalytix Plc (RNLX) Q1 2024 Earnings Call Transcript
Renalytix Plc (NASDAQ:RNLX) Q1 2024 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer Howard Doran...
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical m...
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, Nov...
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood t...
Renalytix Plc (RNLX) Q4 2023 Earnings Call Transcript
Renalytix Plc (NASDAQ:RNLX) Q4 2023 Earnings Conference Call September 28, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer Thomas McLa...
Renalytix Reports Full Year Fiscal 2023 Results
LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical ...
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28
LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September...
Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer
Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort
Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd
World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease World leading, multi-disciplinary...
Renalytix Announces Middle East Distribution Agreement with Vector Pharma
Commercial availability of kidneyintelX.dkd™ expanded to an estimated 4 million DKD Patients in the Middle East
Renalytix: Commercializing First AI Kidney Disease Diagnostic Tool
Renalytix's lead product, KidneyIntelX, an AI diagnostic tool for kidney disease, has received FDA approval and established insurance reimbursement, partnerships, and a sales team. The KidneyIntelX pl...
Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions
12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in p...
Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors
LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognosti...
FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients in the United States